---
title: "Health, Pharma & the Biotechnology Mission for UPSC"
description: "Explore India's health, pharma, and biotechnology ecosystem for UPSC GS-3, covering the BioE3 policy, vaccine platforms, gene therapy, regulators, and"
url: "https://modeldiplomat.com/learn/lessons/upsc-science-technology-health-pharma-the-biotechnology-mission"
---

[New](https://modeldiplomat.com/)

Health, pharma & the biotechnology mission

Read 1 of 3

1/70 XP so far this lesson

Lesson 18 min 20 XP

# Health, pharma & the biotechnology mission

India's health, pharmaceutical and biotechnology ecosystem for UPSC: BioE3 policy, vaccine platforms, gene therapy, regulators, and the missions powering the bioeconomy.

## From Vaccine Maitri to BioE3

India frames biotechnology as a strategic sector. The **Department of Biotechnology (DBT)**, created in 1986 under the Ministry of Science and Technology, is the apex policy body, supported by its public-sector enterprise **BIRAC (Biotechnology Industry Research Assistance Council, 2012)**, which de-risks startup innovation. The flagship vision is the **BioE3 Policy (‘Biotechnology for Economy, Environment and Employment’)**, approved by the Union Cabinet on 24 August 2024. BioE3 targets high-performance biomanufacturing across six themes: bio-based chemicals and enzymes; functional foods and smart proteins; precision biotherapeutics; climate-resilient agriculture; carbon capture and utilisation; and marine and space biotechnology. It establishes Biomanufacturing and Bio-AI hubs and Biofoundries, and explicitly aims to expand India's **bioeconomy**, which the Economic Survey and DBT report grew from about USD 10 billion (2014) to over USD 150 billion (2024), with a target of USD 300 billion by 2030.

## Mission COVID Suraksha and the platform legacy

India's vaccine capability is its global calling card. **Covaxin (BBV152)**, an inactivated whole-virion vaccine, was developed by Bharat Biotech with the **ICMR–National Institute of Virology, Pune**, and received WHO Emergency Use Listing on 3 November 2021. **Covishield** was the Serum Institute of India's licensed manufacture of the Oxford–AstraZeneca adenoviral-vector vaccine. **ZyCoV-D** (Zydus Cadila), cleared by the DCGI in August 2021, was the world's first approved **plasmid DNA vaccine** and India's first needle-free (jet-injector) vaccine. **CORBEVAX** (Biological E) was a protein sub-unit vaccine. **iNCOVACC** became the world's first intranasal COVID vaccine to receive approval (2022). These were financed partly through **Mission COVID Suraksha** under the Atmanirbhar Bharat 3.0 package.

## Regulators and the gene-therapy frontier

The drug regulator is the **Central Drugs Standard Control Organisation (CDSCO)**, headed by the **Drugs Controller General of India (DCGI)**, operating under the **Drugs and Cosmetics Act, 1940** and the **New Drugs and Clinical Trials Rules, 2019**. For genetically engineered organisms and products, the **Genetic Engineering Appraisal Committee (GEAC)** under the Ministry of Environment (per the 1989 Rules of the Environment Protection Act, 1986) is the apex approver. In October 2023 GEAC recommended environmental release of **DMH-11**, India's first transgenic (GM) mustard hybrid — a recurring Prelims hook. On the cutting edge, in October 2024 the CDSCO approved **NexCAR19**, India's first indigenously developed **CAR-T cell therapy** (developed by IIT Bombay, Tata Memorial Centre and ImmunoACT) for B-cell cancers, dramatically cheaper than imported equivalents. India is also advancing **gene therapy for sickle cell disease**, aligned with the **National Sickle Cell Anaemia Elimination Mission (2023, target 2047)**.

One question, then back to the lesson

Ask about this lesson